Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 701–800 of 1,026

1. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
   Thiem, Alexander, Hesbacher, Sonja, Kneitz, Hermann, di Primio, Teresa, Heppt, Markus V., Hermanns, Heike M., Goebeler, Matthias, Meierjohann, Svenja, Houben, Roland, Schrama, David · 2019 · Journal of Experimental & Clinical Cancer Research
2. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
   Weipeng Wang, Fang Li, Yong Mao, Huan Zhou, Jing Sun, Rui Li, Cuiping Liu, Weichang Chen, Dong Hua, Xueguang Zhang · 2013 · Human Genetics
3. B7-H1 Blockade Increases Survival of Dysfunctional CD8+ T Cells and Confers Protection against Leishmania donovani Infections
   Trupti Joshi, Susana Rodriguez, Vladimir Perović, Ian Andrew Cockburn, Simona Stäger · 2009 · PLoS Pathogens
4. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
   Hongnan Mo, Jing Huang, Jiachen Xu, Xuelian Chen, Dawei Wu, Dong Qu, Xi Wang, Bo Lan, Xingyuan Wang, Jianping Xu et al. · 2018 · British Journal of Cancer
5. CAR T Cell Therapy for Neuroblastoma
   Rebecca M. Richards, Elena Sotillo, Robbie G. Majzner · 2018 · Frontiers in Immunology
6. Sex and Gender Disparities in Melanoma
   Maria Bellenghi, Rossella Puglisi, Giada Pontecorvi, Alessandra De Feo, Alessandra Carè, Gianfranco Mattia · 2020 · Cancers
7. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
   Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou� Huang, Mohammad Reza Karimzadeh, Amir Abbas Momtazi‐Borojeni, Sheng Chen · 2021 · Journal for ImmunoTherapy of Cancer
8. Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo
   Toshiro Ito, Takuya Ueno, Michael R. Clarkson, Xueli Yuan, Mollie M. Jurewicz, Hideo Yagita∥, Miyuki Azuma, Arlene H. Sharpe, Hugh Auchincloss, Mohamed H. Sayegh et al. · 2005 · The Journal of Immunology
9. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
   Lin, Kailong, Cheng, Jianan, Yang, Tao, Li, Yongsheng, Zhu, Bo · 2015 · Biochemical and Biophysical Research Communications
10. Improving cancer immunotherapy by targeting tumor-induced immune suppression
    Trina J. Stewart, Mark John Smyth · 2011 · Cancer and Metastasis Reviews
11. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
    Alexander M. Lesokhin, Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2015 · Science Translational Medicine
12. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
    Tahiro Shin, Kiyoshi Yoshimura, Takako Shin, Emily B. Crafton, Haruo Tsuchiya, Franck Housseau, Haruhiko Koseki, Richard David Schulick, Lieping Chen, Drew M. Pardoll · 2005 · The Journal of Experimental Medicine
13. PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
    Wojciech G. Lesniak, Samit Chatterjee, Matthew Gabrielson, Ala Lisok, Bryan L. Wharram, Martin G. Pomper, Sridhar Nimmagadda · 2016 · Bioconjugate Chemistry
14. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
    James Xunhai Xu, Virginia Ellen Maher, Lijun Zhang, Shenghui W. Tang, Rajeshwari Sridhara, Amna Ibrahim, Geoffrey Kim, Richard Pazdur · 2017 · The Oncologist
15. Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment
    Samaresh Sau, Hashem O. Alsaab, Ketki Bhise, Rami M. Alzhrani, Ghazal Nabil, Arun K. Iyer · 2018 · Journal of Controlled Release
16. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression
    Wei Zhang, Wenqun Zhong, Beike Wang, Jiegang Yang, Jingbo Yang, Ziyan Yu, Zhiyuan Qin, Alex Shi, Wei Xu, Cathy Zheng et al. · 2022 · Developmental Cell
17. Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
    Bailey, Christopher M., Liu, Yan, Liu, Mingyue, Du, Xuexiang, Devenport, Martin, Zheng, Pan, Liu, Yang, Wang, Yin · 2022 · Journal of Clinical Investigation
18. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
    Adam Tully Waickman, Angela Alme, Liana Senaldi, Paul E. Zarek, Maureen R. Horton, Jonathan D. Powell · 2011 · Cancer Immunology Immunotherapy
19. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder
    Evanguelos N. Xylinas, Brian D. Robinson, Luis Alex Kluth, Bjoern G. Volkmer, Richard E. Hautmann, R. Küfer, Marc Zerbib, E.D. Kwon, Robert Houston Thompson, Stephen Anthony Boorjian et al. · 2013 · European Journal of Surgical Oncology
20. Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
    Lucy Lee, Manish Gupta, Srikumar Sahasranaman · 2015 · The Journal of Clinical Pharmacology
21. Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction
    Paul C. McDonald, Shawn C. Chafe, Shoukat Dedhar · 2016 · Frontiers in Cell and Developmental Biology
22. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
    Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen et al. · 2017 · Clinical Cancer Research
23. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors
    Alok V. Joglekar, Michael Troy Leonard, John David Jeppson, M Swift, Guideng Li, Stephanie K. Wong, Songming Peng, Jesse Meir Zaretsky, James R. Heath, Antoni Ribas et al. · 2019 · Nature Methods
24. Extracellular Vesicles in Cancer Detection: Hopes and Hypes
    Ye Hu, Joy Wolfram, Sudhir Srivastava · 2020 · Trends in cancer
25. Strategies of Tumor Immune Evasion
    Barbara Seliger · 2005 · BioDrugs
26. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer
    Martin Loos, Nathalia A. Giese, Jorg H. Kleeff, Thomas Giese, Matthias M. Gaida, Frank Bergmann, Melanie Laschinger, Markus Wolfgang Büchler, Helmut Frieß · 2008 · Cancer Letters
27. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
    Riki Okita, Ai Maeda, Katsuhiko Shimizu, Yuji Nojima, Shinsuke Saisho, Masao Nakata · 2017 · Cancer Immunology Immunotherapy
28. Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy
    Si-Pei Wu, Ri-Qiang Liao, Hai‐Yan Tu, Wenjun Wang, Zhong‐Yi Dong, Shu‐Mei Huang, Wei‐Bang Guo, Lan-ying Gou, Huiwen Sun, Qi Zhang et al. · 2017 · Journal of Thoracic Oncology
29. Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer
    Ya Gao, Shuzhen Shi, Wenjuan Ma, Ji Chen, Yitong Cai, Long Ge, Lun Li, Jiarui Wu, Jinhui Tian · 2019 · International Immunopharmacology
30. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer
    Martin Loos, Dennis Martin Hedderich, Malte Ottenhausen, Nathalia A. Giese, Melanie Laschinger, Iréne Esposito, Jorg H. Kleeff, Helmut Friess · 2009 · BMC Cancer
31. PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors
    Seifert, Adrian M., Zeng, Shan, Zhang, Jennifer Q., Kim, Teresa S., Cohen, Noah A., Beckman, Michael J., Medina, Benjamin D., Maltbaek, Joanna H., Loo, Jennifer K., Crawley, Megan H. et al. · 2017 · Clinical Cancer Research
32. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
    Frauke M. Schnorfeil, Felix Sebastian Lichtenegger, Katharina Emmerig, Miriam Schlueter, Julia S. Neitz, Rika Draenert, Wolfgang Hiddemann, Marion S. Subklewe · 2015 · Journal of Hematology & Oncology
33. Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
    Anchalee Rawangkan, Pattama Wongsirisin, Kozue Namiki, Keisuke Iida, Yasuhito Kobayashi, Yoshihiko Shimizu, Hirota Fujiki, Masami Suganuma · 2018 · Molecules
34. Immune checkpoint inhibitors in cancer therapy
    S. Eika, Liu Peng, Renato B. Baleeiro, R. Nicholas, Yuan Ming, Wang Yaohe · 2017 · Journal of Biomedical Research
35. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
    Xiaoying Sun, Raheleh Roudi, Ting Dai, Shangya Chen, Bin Fan, Hongjin Li, Yaqiong Zhou, Min Zhou, Bo Zhu, Chengqian Yin et al. · 2019 · BMC Cancer
36. ARF6 and AMAP1 are major targets of <i>KRAS</i> and <i>TP53</i> mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
    Hashimoto, Shigeru, Furukawa, Shotaro, Hashimoto, Ari, Tsutaho, Akio, Fukao, Akira, Sakamura, Yurika, Parajuli, Gyanu, Onodera, Yasuhito, Otsuka, Yutaro, Handa, Haruka et al. · 2019 · Proceedings of the National Academy of Sciences
37. Regulatory T Cells in Cancer
    Plitas, George, Rudensky, Alexander Y. · 2020 · Annual Review of Cancer Biology
38. Cancer immunotherapies, their safety and toxicity
    Gheath Alatrash, Haroon Jakher, Patricia Stafford, Elizabeth Ann Mittendorf · 2013 · Expert Opinion on Drug Safety
39. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino, Gerardo Botti, Paul C. Lorigan, Giuseppe Valentino Masucci, Jason Hipp, Christine E. Horak, Ignacio Melero, Paolo A. Ascierto · 2016 · Drugs
40. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
    Jie Wang, Keke Fei, Jing Hua, Zhihai Wu, Weiwei Wu, Shuaixiang Zhou, Haiqing Ni, Bingliang Chen, Yan Xiong, Yanpeng Liu et al. · 2019 · mAbs
41. Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX‐2 and PD‐L1
    S. Jin, Muhammad Nafees, Yuewen Sun, Yehong Tan, Hao Yuan, Dongfan Song, Zijian Guo, Xiaoyong Wang · 2020 · Angewandte Chemie International Edition
42. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives
    Suprabhat Mukherjee, Ritwik Patra, Payam Behzadi, Andrea Masotti, Alessandro Paolini, Meysam Sarshar · 2023 · Frontiers in Immunology
43. Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma
    Shari Pilon‐Thomas, Amy Mackay, Nasreen A. Vohra, James J. Mulé · 2010 · The Journal of Immunology
44. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
    Hojabr Kakavand, James S. Wilmott, Alexander Maxwell Menzies, Ricardo E. Vilain, Lauren Elaine Haydu, Jennifer Holmes Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina Venetia Long et al. · 2015 · Clinical Cancer Research
45. Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
    Aaron Prodeus, Aws Abdul‐Wahid, Nicholas William Fischer, Eric H.‐B. Huang, Marzena Cydzik, Jean Gariépy · 2015 · Molecular Therapy — Nucleic Acids
46. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
    Yongshu Li, Fangfei Li, Feng Jiang, Xiaoqing Lv, Rongjiang Zhang, Aiping Lü, Ge Zhang · 2016 · International Journal of Molecular Sciences
47. Not All Immune Checkpoints Are Created Equal
    Annika De Sousa Linhares, Judith Maria Leitner, Katharina Grabmeier‐Pfistershammer, Peter Steinberger · 2018 · Frontiers in Immunology
48. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy
    Jingwei Sun, Lu Qiao, Miguel F. Sanmamed, Jun Wang · 2020 · Clinical Cancer Research
49. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
    Daniela Massi, Davide Brusa, Barbara Merelli, Michela Ciano, Valentina Audrito, Sara Serra, Roberta Buonincontri, Gianna Baroni, Romina Nassini, Daiana Minocci et al. · 2014 · Annals of Oncology
50. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
    Chan-Young Ock, Sehui Kim, Bhumsuk Keam, Miso Kim, Tae Min Kim, Jin-Ho Kim, Yoon Kyung Jeon, Ju‐Seog Lee, Seong Keun Kwon, Jeong Hun Hah et al. · 2016 · Oncotarget
51. Immune Checkpoint in Glioblastoma: Promising and Challenging
    Jing Huang, Fangkun Liu, Zhixiong Liu, Hui Tang, Haishan Wu, Qian-Ni Gong, Jindong Chen · 2017 · Frontiers in Pharmacology
52. Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
    Yosi Gilad, Gary Gellerman, David Michael Lonard, Bert W. O’Malley · 2021 · Cancers
53. Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
    Tianyu Wang, Shi Cai, Yao Cheng, Wanheng Zhang, Minmin Wang, Huiyong Sun, Binghua Guo, Zheng Li, Yibei Xiao, Sheng Jiang · 2022 · Journal of Medicinal Chemistry
54. Cancer Immunoediting in the Era of Immuno-oncology
    Matthew M. Gubin, Matthew D. Vesely · 2022 · Clinical Cancer Research
55. The clinical landscape of CAR NK cells
    Lasse Vedel Jørgensen, Emil Birch Christensen, Mike Bogetofte Barnkob, Torben Barington · 2025 · Experimental Hematology and Oncology
56. B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism
    Xingluo Liu, Jian Xin Gao, Jing Wen, Lijie Yin, Ou Li, Tao Zuo, Thomas Frank Gajewski, Yang‐Xin Fu, Pan Zheng, Yang Liu · 2003 · The Journal of Experimental Medicine
57. Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
    Florian Wimmers, Gerty Schreibelt, Annette E. Sköld, Carl Gustav Figdor, I. Jolanda M. de Vries · 2014 · Frontiers in Immunology
58. The immune microenvironment of breast ductal carcinoma in situ
    Elizabeth D. Thompson, Janis Marie Taube, Hillary R. Elwood, Rajni B Sharma, Alan Keith Meeker, Hind Nassar Warzecha, Pedram Argani, Ashley Cimino‐Mathews, Leisha A. Emens · 2016 · Modern Pathology
59. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
    Lavinia Anne Spain, Robert M. Higgins, Kasthurirangan Gopalakrishnan, Samra Turajlic, Martin Eric Gore, James Larkin · 2016 · Annals of Oncology
60. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors
    Emily A. Sloan, Kari Lassen Ring, Brian C. Willis, Susan C. Modesitt, Anne M. Mills · 2016 · The American Journal of Surgical Pathology
61. Unconventional Ways to Live and Die: Cell Death and Survival in Development, Homeostasis, and Disease
    Swapna Aravind Gudipaty, Christopher M. Conner, Jody Rosenblatt, Denise J. Montell · 2018 · Annual Review of Cell and Developmental Biology
62. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
    Mengke Niu, Yiming Liu, Ming Yi, Dechao Jiao, Kongming Wu · 2022 · Frontiers in Immunology
63. PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
    Dawn E. Dolan, Shilpa Gupta · 2014 · Cancer Control
64. Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
    Alfred Zippelius, Jens Schreiner, Petra Herzig, Philipp Müller · 2015 · Cancer Immunology Research
65. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
    Hongshan Li, Jingyu Yu, Chao Liu, Jiang Liu, Sriram Subramaniam, Hong Zhao, Gideon Michael Blumenthal, David C. Turner, Claire H. Li, Malidi Ahamadi et al. · 2017 · Journal of Pharmacokinetics and Pharmacodynamics
66. Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
    James Mwikya Reuben, Bang-Ning Lee, Changping Li, Jesús Gómez-Navarro, Viviana A. Bozon, Charla A. Parker, Ingrid M. Hernandez, Carolina Gutiérrez, Gabriel Lopez‐Berestein, Luis H. Camacho · 2006 · Cancer
67. B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis
    Takaaki Arigami, Norihiko Narita, Ryuichi Mizuno, Linhda Nguyen, Xing Ye, Alice P. Chung, Armando E. Giuliano, Dave S.�B. Hoon · 2010 · Annals of Surgery
68. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?
    Margret Ehlers, Matthias Schott · 2014 · Trends in Endocrinology and Metabolism
69. Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
    Zappasodi, Roberta, Budhu, Sadna, Hellmann, Matthew D., Postow, Michael A., Senbabaoglu, Yasin, Manne, Sasikanth, Gasmi, Billel, Liu, Cailian, Zhong, Hong, Li, Yanyun et al. · 2018 · Cancer Cell
70. USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
    Xing Huang, Qi Zhang, Yu Lou, Junli Wang, Xinyu Zhao, Lin Wang, Xiaozhen Zhang, Shanshan Li, Yulan Zhao, Qi Chen et al. · 2019 · Cancer Immunology Research
71. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy
    Dávid Győri, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen Joseph Shuttleworth, Klaus Okkenhaug, Len Stephens, Phillip T. Hawkins · 2018 · JCI Insight
72. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer
    Xin Jin, Zhaorui Liu, Dongxiao Yang, Kai Yin, Xusheng Chang · 2022 · Frontiers in Immunology
73. B7-DC Regulates Asthmatic Response by an IFN-γ-Dependent Mechanism
    Koichiro Matsumoto, Hiromasa Inoue, Takako Nakano, Miyuki Tsuda, Yuki Yoshiura, Satoru Fukuyama, Fumihiko Tsushima, Tomoaki Hoshino, Hisamichi Aizawa, Hisaya Akiba et al. · 2004 · The Journal of Immunology
74. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
    Karl S. Peggs, Sergio A. Quezada, James Patrick Allison · 2009 · Clinical & Experimental Immunology
75. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
    Naoya Maekawa, Satoru Konnai, Tomohiro Okagawa, Asami Nishimori, Ryoyo Ikebuchi, Yusuke Izumi, Satoshi Takagi, Yumiko Kagawa, Chie Nakajima, Yasuhiko Suzuki et al. · 2016 · PLoS ONE
76. PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
    Rui Zhao, Yinghan Song, Yong Wang, Yuqian Huang, Zhigui Li, Yaping Cui, Mengshi Yi, Lin Xia, Wen Zhuang, Xiaoting Wu et al. · 2019 · Cell Proliferation
77. A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
    Miguel F. Sanmamed, Xinxin Nie, Shruti Desai, Franz Villarroel‐Espíndola, Ti Badri, Dejian Zhao, Anthony W. Kim, Lan Ji, Tianxiang Zhang, Edward Quinlan et al. · 2021 · Cancer Discovery
78. Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells
    Natalia Martín‐Orozco, Yufeng Li, Yi‐Jun Wang, Shijuan Liu, Patrick Hwu, Yong‐Jun Liu, Chen Dong, Laszlo George Radvanyi · 2010 · Cancer Research
79. Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma
    Iñigo Tirapu, Eduardo Huarte, Cristiana Guiducci, Ainhoa Arina, Mikel Zaratiegui, Oihana Murillo, Álvaro González, Carmen Berasain, Pedro Berraondo, Puri Fortes et al. · 2006 · Cancer Research
80. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
    Zhenkui Pan, Feng Ye, Xuan Wu, Han‐Xiang An, Jingxun Wu · 2015 · PubMed Central
81. PD-1 Blockers
    Jedd D. Wolchok · 2015 · Cell
82. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune
    Zhansheng Jiang, Yanfang Yang, Yinli Yang, Yu Zhang, Zhensong Yue, Zhanyu Pan, Xiubao Ren · 2017 · Biomedicine & Pharmacotherapy
83. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
    Etienne D. Foucher, Clément Ghigo, Salem Chouaı̈b, Jérôme Galon, Juan Iovanna, Daniel Olive · 2018 · Frontiers in Immunology
84. Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors
    Jack A. Prescott, Simon J. Cook · 2018 · Cells
85. Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
    Jang‐June Park, Emily P. Thi, Victor H. Carpio, Yingzhi Bi, Andrew G. Cole, Bruce D. Dorsey, Kristi Yi Fan, Troy O. Harasym, Christina L. Iott, Salam Kadhim et al. · 2021 · Nature Communications
86. Dual biological effects of the cytokines interleukin-10 and interferon-γ
    Wilke, Cailin Moira, Wei, Shuang, Wang, Lin, Kryczek, Ilona, Kao, John, Zou, Weiping · 2011 · Cancer Immunology Immunotherapy
87. Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
    Wendy A. Cooper, Prudence Anne Russell, Maya Cherian, Edwina Duhig, David Godbolt, Peter J. Jessup, Christine Khoo, Connull Leslie, Annabelle M. Mahar, David F. C. Moffat et al. · 2017 · Clinical Cancer Research
88. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
    Qingshui Wang, Wei Lin, Xiaoqiong Tang, Suhuan Li, Libin Guo, Yao Lin, Hang Fai Kwok · 2017 · International Journal of Molecular Sciences
89. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release
    Shu Lian, Ruizhi Xie, Yuying Ye, Xiaodong Xie, Shuhui Li, Yusheng Lu, Bifei Li, Yunlong Cheng, Vladimir L. Katanaev, Lee Jia · 2019 · EBioMedicine
90. Role of PD-1 in HIV Pathogenesis and as Target for Therapy
    Filippos Porichis, DE Kaufmann · 2011 · Current HIV/AIDS Reports
91. Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells
    Jean Kim, Allen C. Myers, Lieping Chen, Drew M. Pardoll, Quynh Ai Truong-Tran, Andrew P. Lane, John F. McDyer, Lowella V. Fortuno, Robert P. Schleimer · 2005 · American Journal of Respiratory Cell and Molecular Biology
92. Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
    Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Keunchil Park, Jong‐Mu Sun, Young Hyeh Ko, Chung‐Hwan Baek, Young‐Ik Son, Han Sin Jeong, Yong Chan Ahn et al. · 2015 · Cancer Research and Treatment
93. B7‐H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
    Ryō Yamamoto, Momoko Nishikori, Masaharu Tashima, Tomomi Sakai, Tatsuo Ichinohe, Akifumi Takaori‐Kondo, Katsuyuki Ohmori, Takashi Uchiyama · 2009 · Cancer Science
94. Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage
    Huston Davis Adkisson, Curt L. Milliman, X. Zhang, Kelsey A. Mauch, Richard Thomas Maziarz, Philip R. Streeter · 2009 · Stem Cell Research
95. Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients
    Sytse J. Piersma · 2011 · Cancer Microenvironment
96. Combination of Radiotherapy and Immune Checkpoint Inhibitors
    Karsten A. Pilones, Claire Vanpouille‐Box, Sandra Demaria · 2014 · Seminars in Radiation Oncology
97. PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
    Yawei Liu, R. Carlsson, Malene Ambjørn, Maruf Hasan, Wiaam Badn, Anna Darabi, Peter Siesjö, Shohreh Issazadeh‐Navikas · 2013 · Journal of Neuroscience
98. Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
    Anja Derer, Martina Spiljar, Monika Bäumler, Markus Hecht, Rainer Fietkau, Benjamin Frey, Udo S. Gaipl · 2016 · Frontiers in Immunology
99. Checkpoint inhibitors in hematological malignancies
    Chi Young Ok, Ken H. Young · 2017 · Journal of Hematology & Oncology
100. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
     Wei‐fa Yang, May Chun Mei Wong, Peter James Thomson, Kar Yan Li, Yu‐Xiong Su · 2018 · Oral Oncology